{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:55:51Z","timestamp":1791165351302,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11739-022-03156-w","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T11:18:45Z","timestamp":1670498325000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bleeding and thrombotic events in atrial fibrillation patients with cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Farcomeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"1","key":"3156_CR1","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","volume":"19","author":"CB Jakobsen","year":"2019","unstructured":"Jakobsen CB et al (2019) Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study. BMC Cancer 19(1):1105","journal-title":"BMC Cancer"},{"key":"3156_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.blre.2019.03.005","volume":"35","author":"G Chu","year":"2019","unstructured":"Chu G et al (2019) Atrial fibrillation and cancer\u2014an unexplored field in cardiovascular oncology. Blood Rev 35:59\u201367","journal-title":"Blood Rev"},{"key":"3156_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pcad.2021.04.004","volume":"66","author":"D Menichelli","year":"2021","unstructured":"Menichelli D et al (2021) Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment. Prog Cardiovasc Dis 66:28\u201336","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"3156_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano JL et al (2017) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19(1):9\u201342","journal-title":"Eur J Heart Fail"},{"key":"3156_CR5","doi-asserted-by":"crossref","unstructured":"Menichelli D et al. (2021) Cancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment. Prog Cardiovasc Dis 66:28\u201336","DOI":"10.1016\/j.pcad.2021.04.004"},{"key":"3156_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijcard.2019.08.021","volume":"296","author":"YP Hung","year":"2019","unstructured":"Hung YP et al (2019) Risk and predictors of subsequent cancers of patients with newly-diagnosed atrial fibrillation\u2014a nationwide population-based study. Int J Cardiol 296:81\u201386","journal-title":"Int J Cardiol"},{"issue":"16","key":"3156_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008987","volume":"7","author":"CL Fanola","year":"2018","unstructured":"Fanola CL et al (2018) Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF\u2014TIMI 48 Trial. J Am Heart Assoc 7(16):e008987","journal-title":"J Am Heart Assoc"},{"key":"3156_CR8","doi-asserted-by":"crossref","unstructured":"Chen, S.T., et al., Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes, 2019; 5(2): 145\u2013152.","DOI":"10.1093\/ehjqcco\/qcy040"},{"key":"3156_CR9","doi-asserted-by":"crossref","unstructured":"Melloni, C., et al., Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. Am J Med, 2017. 130(12): p. 1440\u20131448 e1.","DOI":"10.1016\/j.amjmed.2017.06.026"},{"issue":"1","key":"3156_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2015-000290","volume":"2","author":"L Fauchier","year":"2015","unstructured":"Fauchier L et al (2015) Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart 2(1):e000290","journal-title":"Open Heart"},{"issue":"23","key":"3156_CR11","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","volume":"68","author":"A Gomez-Outes","year":"2016","unstructured":"Gomez-Outes A et al (2016) Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 68(23):2508\u20132521","journal-title":"J Am Coll Cardiol"},{"key":"3156_CR12","doi-asserted-by":"crossref","unstructured":"Pastori, D., et al., The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. Eur J Intern Med, 2021. 85: p. 80\u201385.","DOI":"10.1016\/j.ejim.2020.12.011"},{"issue":"12","key":"3156_CR13","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1002\/ijc.33179","volume":"147","author":"D Pastori","year":"2020","unstructured":"Pastori D et al (2020) Cancer-specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO-AF study. Int J Cancer 147(12):3424\u20133430","journal-title":"Int J Cancer"},{"key":"3156_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.breast.2019.05.017","volume":"46","author":"A Pardo Sanz","year":"2019","unstructured":"Pardo Sanz A et al (2019) Current status of anticoagulation in patients with breast cancer and atrial fibrillation. Breast 46:163\u2013169","journal-title":"Breast"},{"issue":"3","key":"3156_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104560","volume":"29","author":"S Aspberg","year":"2020","unstructured":"Aspberg S et al (2020) Risk of ischemic stroke and major bleeding in patients with atrial fibrillation and cancer. J Stroke Cerebrovasc Dis 29(3):104560","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"3156_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"3156_CR17","unstructured":"Wells, G.A., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014 [cited Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp; Available from: Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"3156_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"3156_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"3156_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"issue":"11","key":"3156_CR21","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00277-016-2783-y","volume":"95","author":"AS de Freitas","year":"2016","unstructured":"de Freitas AS, Alvarez-Larran A (2016) Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants. Ann Hematol 95(11):1903\u20131904","journal-title":"Ann Hematol"},{"issue":"2","key":"3156_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.thromres.2015.06.011","volume":"136","author":"G Denas","year":"2015","unstructured":"Denas G et al (2015) Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy. Thromb Res 136(2):488","journal-title":"Thromb Res"},{"issue":"3","key":"3156_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","volume":"3","author":"C Melloni","year":"2017","unstructured":"Melloni C et al (2017) Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 3(3):192\u2013197","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"6","key":"3156_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/2047487318759858","volume":"25","author":"M D'Souza","year":"2018","unstructured":"D\u2019Souza M et al (2018) CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol 25(6):651\u2013658","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"3156_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/14017431.2019.1638517","volume":"53","author":"M D'Souza","year":"2019","unstructured":"D\u2019Souza M et al (2019) Atrial fibrillation and anticoagulation in patients with breast cancer. Scand Cardiovasc J 53(5):247\u2013254","journal-title":"Scand Cardiovasc J"},{"issue":"6","key":"3156_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cam4.1054","volume":"6","author":"AG Ording","year":"2017","unstructured":"Ording AG et al (2017) Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 6(6):1165\u20131172","journal-title":"Cancer Med"},{"issue":"5","key":"3156_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.amjcard.2017.11.027","volume":"121","author":"A Elbadawi","year":"2018","unstructured":"Elbadawi A et al (2018) In-hospital cerebrovascular outcomes of patients with atrial fibrillation and cancer (from the national inpatient sample database). Am J Cardiol 121(5):590\u2013595","journal-title":"Am J Cardiol"},{"key":"3156_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.07.138","volume":"269","author":"MC Vedovati","year":"2018","unstructured":"Vedovati MC et al (2018) Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study. Int J Cardiol 269:152\u2013157","journal-title":"Int J Cardiol"},{"issue":"12","key":"3156_CR29","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/cncr.33470","volume":"127","author":"D Pastori","year":"2021","unstructured":"Pastori D et al (2021) Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer 127(12):2122\u20132129","journal-title":"Cancer"},{"key":"3156_CR30","doi-asserted-by":"crossref","unstructured":"Pastori, D., et al., Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: A nationwide cohort study. Cancer, 2021.","DOI":"10.1093\/europace\/euab116.293"},{"issue":"2","key":"3156_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1055\/s-0039-3400300","volume":"120","author":"I Cavallari","year":"2020","unstructured":"Cavallari I et al (2020) Efficacy and safety of nonvitamin k oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 120(2):314\u2013321","journal-title":"Thromb Haemost"},{"key":"3156_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.590768","volume":"8","author":"LA Hajjar","year":"2021","unstructured":"Hajjar LA, Fonseca SMR, Machado TIV (2021) Atrial fibrillation and cancer. Front Cardiovasc Med 8:590768","journal-title":"Front Cardiovasc Med"},{"key":"3156_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fcvm.2019.00017","volume":"6","author":"D Pastori","year":"2019","unstructured":"Pastori D et al (2019) Tailored practical management of patients with atrial fibrillation: a risk factor-based approach. Front Cardiovasc Med 6:17","journal-title":"Front Cardiovasc Med"},{"key":"3156_CR34","doi-asserted-by":"crossref","unstructured":"Adamson, J.W., The anemia of inflammation\/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program, 2008: p. 159\u201365.","DOI":"10.1182\/asheducation-2008.1.159"},{"issue":"2","key":"3156_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/apm.2017.11.01","volume":"7","author":"C Johnstone","year":"2018","unstructured":"Johnstone C, Rich SE (2018) Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 7(2):265\u2013273","journal-title":"Ann Palliat Med"},{"issue":"10","key":"3156_CR36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J et al (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612\u20131676","journal-title":"Europace"},{"issue":"6","key":"3156_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.19128","volume":"5","author":"TF Wang","year":"2022","unstructured":"Wang TF et al (2022) Hemorrhage risk among patients with breast cancer receiving concurrent direct oral anticoagulants with tamoxifen vs aromatase inhibitors. JAMA Netw Open 5(6):e2219128","journal-title":"JAMA Netw Open"},{"key":"3156_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.16","volume":"7","author":"S Viborg","year":"2016","unstructured":"Viborg S et al (2016) Lower gastrointestinal bleeding and risk of gastrointestinal cancer. Clin Transl Gastroenterol 7:e162","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"3156_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003998","volume":"11","author":"J Aisenberg","year":"2018","unstructured":"Aisenberg J et al (2018) Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction). Circ Cardiovasc Qual Outcomes 11(5):e003998","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"21","key":"3156_CR40","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","volume":"66","author":"MW Sherwood","year":"2015","unstructured":"Sherwood MW et al (2015) Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF Trial. J Am Coll Cardiol 66(21):2271\u20132281","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"3156_CR41","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012540","volume":"8","author":"Y Deng","year":"2019","unstructured":"Deng Y et al (2019) Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 8(14):e012540","journal-title":"J Am Heart Assoc"},{"key":"3156_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ahj.2016.12.008","volume":"185","author":"BD Westenbrink","year":"2017","unstructured":"Westenbrink BD et al (2017) Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 185:140\u2013149","journal-title":"Am Heart J"},{"issue":"Suppl 1","key":"3156_CR43","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/S0049-3848(20)30400-X","volume":"191","author":"A Leader","year":"2020","unstructured":"Leader A, Gurevich-Shapiro A, Spectre G (2020) Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia. Thromb Res 191(Suppl 1):S68\u2013S73","journal-title":"Thromb Res"},{"issue":"12","key":"3156_CR44","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","volume":"129","author":"L Fauchier","year":"2016","unstructured":"Fauchier L et al (2016) Causes of death and influencing factors in patients with atrial fibrillation. Am J Med 129(12):1278\u20131287","journal-title":"Am J Med"},{"issue":"3","key":"3156_CR45","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.mayocp.2020.06.057","volume":"96","author":"D Pastori","year":"2021","unstructured":"Pastori D et al (2021) Long-term risk of major adverse cardiac events in atrial fibrillation patients on direct oral anticoagulants. Mayo Clin Proc 96(3):658\u2013665","journal-title":"Mayo Clin Proc"},{"key":"3156_CR46","doi-asserted-by":"crossref","unstructured":"Liu, F., et al., Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. Front Cardiovasc Med, 2021. 8: p. 766377.","DOI":"10.3389\/fcvm.2021.766377"},{"key":"3156_CR47","doi-asserted-by":"crossref","unstructured":"Chen, S., et al., Patterns of Anticoagulation Use in Atrial Fibrillation and Active Cancer: Observations From Medicare. Circulation, 2021. 144(A12118).","DOI":"10.1161\/circ.144.suppl_1.12118"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-03156-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-022-03156-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-03156-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T13:52:35Z","timestamp":1678888355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-022-03156-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1007\/s11739-022-03156-w","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}